Cost-Utility Analysis of Rituximab vs Mycophenolate Mofetil for the Treatment of Pemphigus Vulgaris

IMPORTANCE: There is an increasing body of literature that supports the use of rituximab as a first-line steroid-sparing agent in pemphigus vulgaris. However, the cost of rituximab is substantial compared with conventional agents, and there are limited health economic data to justify its use. OBJECT...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Archives of dermatology (1960) 2022-09, Vol.158 (9), p.1013-1021
Hauptverfasser:	Chen, Michelle K. Y, Vissapragada, Ravi, Bulamu, Norma, Gupta, Monisha, Werth, Victoria, Sebaratnam, Deshan Frank
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Australia Autoimmune diseases Biological products Biosimilar Pharmaceuticals Cohort analysis Comments Cost analysis Cost-Benefit Analysis Disease control Female Humans Immunotherapy Male Medical treatment Middle Aged Monoclonal antibodies Mycophenolic Acid - therapeutic use Online First Original Investigation Pemphigus - drug therapy Pharmaceutical Preparations Rituximab - therapeutic use Sensitivity analysis Skin diseases Steroids
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!